Founded 2009; public company (Tel Aviv Stock Exchange) 2010
FlowSense was acquired by Baxter in September 2013.
FlowSense’s URINFO 2000 is based on its patented optical sensing technology and unique disposable. Continuous, real-time data is collected automatically and accessible to clinicians at any time. The product consists of two components:
URINFO is available in two configurations: stand-alone system at the patients’ bedside and integrated with clinical information systems.
Measurement of urine output is a key indicator of a patient’s fluid balance and renal condition, particularly in the critical care setting. Acute kidney injury occurs in approximately 5% of all hospitalized patients and in 30% of critical care patients, resulting in higher costs of care and higher mortality rates.
Mechanical urine meters, which are labor intensive and based on manual volume readings, do not provide urine output data necessary for timely detection and treatment of kidney injury.